Replies to post #437957 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

That's not data.

"Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration"

That's a statement still awaiting data to prove it. Quite important in biotech investing to recognise the difference.